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OBJECTIVE: Primary Sjo¨gren’s syndrome (pSjS) is a chronic autoimmune disease that causes dry eye and mouth.
No laboratory parameters to monitor the activation of this disease have been identified. Therefore, any possible
relationships between salivary and blood myxovirus resistance 1 (MX1) and pSjS must be prospectively studied.
METHODS: Thirty female patients with pSjS, 30 women with rheumatoid arthritis (RA) without secondary
Sjo¨gren’s syndrome (SjS) and 28 healthy control women were enrolled in this investigation. Analyses of MX1 by
the enzyme-linked immunosorbent assay (ELISA) method, SS-A (Ro) and SS-B (La) tests by the strip immunoblot
method, anti-nuclear antibody (ANA) tests by immunofluorescence and the measurement of serum rheumatoid
factor (RF), C3, C4, immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) were
performed.
RESULTS: The serum level of MX1 in patients without Raynaud phenomenon was higher than in those with
Raynaud phenomenon (p:0.029, po0.05, statistically significant). There was a statistically significant positive
association between hemoglobin levels and MX1 serum levels. No statistically significant association was found
among the other parameters. LowMX1 levels were shown to be associated with both a low disease activity score
based on the European League Against Rheumatism (EULAR) Sjo¨gren’s Syndrome Disease Activity Index (ESSDAI)
and hydroxychloroquine use in all patients.
CONCLUSION:MX1 levels have a considerable impact on the assessment of the disease activity in SjS. We believe
that more-comprehensive studies should be performed on patients with pSjS who do not use hydroxychlor-
oquine to prove this relationship and that MX1 levels should be used as a routine marker for the assessment of
pSjS disease activity. Further studies are needed to create awareness of the role that MX1 has in the diagnosis of
pSjS, which may help to uncover novel pathways for new therapeutic modalities.
KEYWORDS: ESSDAI; Hydroxychloroquine; Myxovirus Resistance 1; Sjo¨gren’s syndrome.
’ INTRODUCTION
Sjögren’s syndrome (SjS) is a slowly progressive chronic
autoimmune disease that causes symptoms including dry
mouth (xerostomia) and dry eye (keratoconjunctivitis sicca),
which is mainly attributed to lymphocytic invasion of the
exocrine glands (1). To clinically monitor the disease, the
European League Against Rheumatism (EULAR) Sjögren’s
Syndrome Disease Activity Index (ESSDAI) has been used to
measure disease activation. However, no clearly described
laboratory parameters to monitor disease activation have
been validated (2). The plasma of patients with primary SjS
(pSjS) contains high levels of interferon (IFN)-a. Moreover,
IFN-a increases the mRNA levels in circulating blood cells.
IFN-a-containing epithelial cells and lymphocytes have been
found in the salivary glands. The IFN source is probably the
plasmacytoid dendritic cells that collect in the salivary glands.
In monocytic cell lines, increased levels of the genes that
regulate the expression of type 1 IFN have been observed;
additionally, the high bioactivity of type 1 IFN has been obser-
ved in the serum of patients with pSjS. Myxovirus Resistance
1 (MX1, also known as MxA) is the main mediator of IFN-
based antiviral reactions, and MX1 is strongly affected by
type 1 IFN. Studies have shown that MX1 gene expression in
systemic sclerosis (SS) is a kind of type 1 IFN bioactivity that is
associated with disease activity. These findings have also shed
light on the relationship between high disease SS activity
scores in the ESSDAI and type 1 IFN, and MX1 is a potential
biomarker for SS. In the literature, a cohort study with a total
of 35 patients with pSjS, of whom 21 were IFN-positive
(having an IFN score of 10 and higher) and 14 were interferon-
negative (having an IFN score of less than 10), showed a
significant positive association between the IFN scores, whichDOI: 10.6061/clinics/2019/e631
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were used to measure the bioactivity of type 1 IFN, the ESSDAI
disease activity scores and the serum levels of MX1 (3).
In light of this information, we aimed to assess any
relationship between serum and saliva MX1 protein levels
and disease activity in pSjS patients. The primary endpoint
was defined as the assessment of the relationship between
MX1 protein levels and ESSDAI scores. In this context, we
aimed to evaluate whether the serum or saliva MX1 protein
was ideal for use in clinical practice as a laboratory para-
meter to monitor disease activity and the response to drug
therapy. As secondary endpoints, we aimed to assess the
relationship between MX1 and the serum SS-A (Ro) anti-
body, serum SS-B (La) antibody, serum anti-nuclear antibody
(ANA), serum rheumatoid factor (RF) antibody, immunoglo-
bulin G (IgG), immunoglobulin M (IgM), and immunoglo-
bulin A (IgA), which were previously shown to be important
for the detection and monitoring of pSjS and for describing
the relationship between MX1 and other clinical findings.
Until now, there has been no laboratory marker available for
assessing disease activation in pSjS (2,4).
’ PATIENTS AND METHODS
All procedures were approved by and performed in accor-
dance with the ethical standards of the responsible commit-
tee on human experimentation (institutional) and were in
accordance with the Declaration of Helsinki. The ethics
committee approval for the study was given by Yeditepe
University Institutional Ethics Committee in 2015, and the
doctoral thesis of Yasemin Gul AYDEMIR was conducted at
the same university. Moreover, informed consent forms were
signed by all participants.
From February 2015 to February 2016 (within a 1-year
follow-up period), 30 female pSjS patients, who were diag-
nosed based on the 1996 European classification norms, were
followed up at the rheumatology clinics of 2 university
hospitals (Yeditepe University Hospital and Istanbul Bilim
University Hospital) and received hydroxychloroquine treat-
ment, were enrolled. Additionally, 30 women with rheuma-
toid arthritis (RA) without evidence of secondary SjS and 28
healthy control women were enrolled. Hence, 88 women
(age range: 21-64 years) were evaluated herein in a prospect-
ive and descriptive investigation. Based on their previous
medical histories, patients were excluded for the following
reasons: lymphoma, graft-versus-host disease, radiotherapy
to the head and neck, AIDS, sarcoidosis, hepatitis C infection,
and the use of anticholinergic drugs (neuroleptics, antide-
pressants, antihypertensives, and parasympatholytics). The
demographic characteristics, past medical history and family
medical histories of the patients (age, gender, profession, age
of onset of the disease, family history, systemic diseases,
medications, radiation history, smoking habits, and alcohol
consumption) were recorded in detail, and a detailed physi-
cal examination of the patients was performed at all centers.
The assessment of disease activity was performed with
the ESSDAI in patients with pSjS. Sociodemographic data,
symptoms, the duration of symptoms, age of diagnosis,
laboratory findings, physical examinations, treatment and
disease activity assessment information were obtained after
patients completed the general consent form. When the local
ethics committee had approved the study, serum and saliva
samples were taken from all the volunteers. The analysis of
MX1 by the enzyme-linked immunosorbent assay (ELISA)
method, SS-A (Ro), SS-B (Lo) tests by the strip immunoblot
method, an anti-nuclear antibody (ANA) test by immuno-
fluorescence and the measurement of the concentrations
of serum RF, C3, C4, IgA, IgM and IgG by a nephelometric
method from the serum and saliva samples were performed by
the Tissue Typing Laboratory of Yeditepe University Hospital.
After collecting blood for hemoglobin testing, two extra
tubes with latex were used to collect 5 mL of blood from each
volunteer. Blood samples were centrifuged at 3000 rpm for
10 minutes in the Yeditepe University Hospital Stem Cell
Laboratories after being incubated for half an hour at room
temperature to obtain the patients’ serum. Saliva samples
(2 ml) were taken between 9-11 AM, at least 2 hours after
stopping food and beverage intake. After rinsing their mouths
with water, volunteers were asked to collect the spit over 5 to
15 minutes. The 2-ml saliva samples were aliquoted into five
separate, capped 1.5-ml Eppendorf tubes. The aliquots of the
serum and saliva samples were stored at the Yeditepe University
Hospital Stem Cell Laboratory at -80oC until further analysis.
ELISA tests: The MX1 protein from blood and saliva
samples was tested in accordance with the kit recommenda-
tions by the ELISA (Elabscience® ELISA Kit) method. The
ELISA method has been used in our laboratory for a long
time. Briefly, test sera was added to 96-well ELISA plates that
were coated with antigen or antibody and was incubated for a
certain period of time. Then, the plates were washed twice,
a second incubation with secondary antibodies was performed,
and colorimetric reagent was added. After a short incubation
period, the reaction was stopped with the addition of a
reagent, and spectrophotometric measurement (Epoch ELISA
reader) was performed within no more than 10 minutes. The
quantitation was automatically performed by the plate reader
according to the standard reagent on the plate. One of the most
important criteria for the success of ELISA tests is accurate
pipetting. In our laboratory, the pipettes are regularly
calibrated. The researchers also received detailed training in
this regard. The detection range of the ELISA Kit for MX1 was
1.56-100 ng/mL, and the test method was a double-antibody
sandwich. In regard to sensitivity, the minimum detectable
dose was less than 0.65 ng/mL.
Immunoblot method tests: SS-A (Ro) and SS-B (La) tests
were performed using the strip immunoblot method.
Immunofluorescence tests: ANA immunofluorescence tests
were performed by microscopic examination.
Nephelometric measurements: Serum RF, C3, C4, IgA, IgM
and IgG concentrations were measured by a nephelometric
method.
Statistics: When statistically evaluating the findings obtained
in this study, the SPSS 22 (IBM, Turkey) program was used.
The reliability of the distribution of the parameters was
evaluated by the Shapiro-Wilks test. One-way ANOVA was
used for descriptive statistics, such as the standard deviation,
mean, and frequency, and the two-way intergroup comparisons
of quantitative data were evaluated. When two groups with a
normal distribution were compared, a Student’s t test was
used. However, for abnormally distributed data, the Mann-
Whitney U test was used to compare two groups. Pearson
correlation analysis was used to evaluate the relationships
between the parameters. A po0.05 was considered significant.
’ RESULTS
The patients’ mean age was 48.00±9.78 years. There was
not a significant difference in the mean age among the
groups (p40.05). The age of the patients in the pSjS group
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ranged from 30 to 64 years, and the mean age was
51.07±10.17 years. The age of the patients in the RA
group ranged from 21 to 62 years, and the mean age was
47.27±11:55 years. The age of the patients in the control
group ranged from 33 to 54 years, and the mean age was
45.39±5.96 years.
When evaluating patients with and without pSjS, the
durations of the diseases were 7.57±6.79 and 9.64±6.89
years, respectively. Ocular and oral symptoms were present
in all pSjS patients. The ocular test results showed Schirmer
o5 in 24 (80%) pSjS patients and Schirmer 45 in the
remaining 6 (20%) pSjS patients. The following results were
noted in the pSjS patients: positive histopathology in 6 (20%),
positive salivary gland test results (sialometry and scinti-
graphy) in 30 (100%), pulmonary involvement in 2 (7%),
lymphadenopathy in 9 (30%), parotid gland involvement in 2
(7%), arthralgia or arthritis in 23 (77%), skin involvement in 8
(27%), cryoglobulinemia in 4 (13%), Raynaud phenomenon
in 14 (47%), the presence of the SS-A antibody in 20 (67%),
the presence of the SS-B antibody in 20 (67%), ANA
positivity in 28 (93%), and RF in 4 (13%). While all patients
(n: 30) with pSjS were given hydroxychloroquine, 2 (7%)
were additionally treated with pilocarpine, and 2 (7%) were
also treated with corticosteroids.
No significant difference was detected between the pSjS and
RA groups with regard to the mean serum or saliva MX1
values (p40.05). In regard to the disease duration, there was
no significant difference between the pSjS and RA patient
groups (p40.05). When serum and saliva MX1 values were
compared with sialometry results, ESSDAI scores, and Schirmer
values, no correlations were detected. In the pSjS group,
a positive association was detected between the serum values
of MX1 and hemoglobin levels, and this correlation was
statistically significant. The serum MX1 values in patients
without Raynaud phenomenon were higher than those in
patients with Raynaud phenomenon, and this association was
statistically significant. The differences between the other
parameters were not statistically significant.
There was not a statistically significant difference between
the pSjS and RA groups with regard to the disease duration
(p40.05). The disease duration of the pSjS group ranged
from 0.1 to 24 years, with a mean of 7.57±6.79 years. In the
RA group, the disease duration range was 0.1 to 20 years,
with an average of 4.89±5.39 years. The symptom duration
of the pSjS group ranged from 0.1 to 24 years, with a mean of
9.64±6.89 years.
There were not statistically significant differences between
the groups in terms of the mean serum and salivary MX1
levels (p40.05) (Table 1).
There was no statistically significant relationship between
the serum levels of MX1 and the sialometry results; ESSDAI
scores; and neutrophil, hemoglobin and sedimentation levels
in the pSjS group (p40.05) (Table 2).
There was no statistically significant difference (p40.05)
among the MX1 serum values according to the ESSDAI
scores and Schirmer test results in the pSjS group. There was
not a statistically significant difference (p40.05) between the
serum levels of MX1 according to the presence of lympha-
denopathy, parotid involvement, arthralgia/arthritis, skin
involvement, pulmonary involvement, cryoglobulinemia,
hypocomplementemia and neutropenia. However, the mean
serum level of MX1 in patients with no Raynaud phenom-
enon was significantly higher than that in patients with
Raynaud phenomenon (p:0.029, po0.05) (Table 3).
There were no statistically significant correlations between
the MXI salivary values and the sialometry results and
ESSDAI scores in the pSjS group (p40.05).
There were no statistically significant differences between
the MX1 salivary values according to the ESSDAI scores and
Schirmer test results (p40.05) in the pSjS group.
There were no statistically significant differences (p40.05)
between the serum levels of MX1 according to the presence
of anti-SS-A, anti-SS-B, RF and ANA (Table 4).
There were no statistically significant associations between
the serum levels of MX1 and the C3, C4, IgA, IgG, and IgM
levels (p40.05). However, there was a statistically significant
positive association between hemoglobin levels and serum
MX1 levels (27.3%) (r:0.273, p:0.035, po0.05) (Table 5).
’ DISCUSSION
SjS causes lymphocytes to invade the salivary and lacrimal
glands. Therefore, SjS is known as an autoimmune systemic
disease characterized by dry mouth and eye. If the patient
does not have another autoimmune disease, SjS is defined as
pSjS. SjS is defined as secondary SjS if the patient has another
autoimmune disease, including RA or systemic lupus ery-
thematosus (SLE). Although this disease can be diagnosed
in patients of all ages, it is usually diagnosed between the
4th and 6th decades. SjS is more common in females than in
males, and is diagnosed with a 9:1 female:male ratio (5).
The etiopathogenesis of pSjS is multifactorial. Genetic
susceptibility and hormonal and environmental contributors
have been implicated (6). The ESSDAI has been used to
assess the disease activity. The ESSDAI evaluates the organs
that are affected that contribute to disease activity in
approximately 30% of patients, including pulmonary find-
ings, vasculitis, synovitis, peripheral and central nervous
systems findings, and renal and hematological system
symptoms. In addition to assessing disease activation, treat-
ment success is also monitored by the ESSDAI. Until now,
there has unfortunately been no laboratory available marker
for measuring disease activation (7).
MX1 is the main mediator of the interferon-based reaction
against viruses and is strongly regulated by type 1 IFN. In
previous studies, MX1 gene expression in SS was shown to
Table 1 - The evaluation of the serum and saliva levels of MX1 in
the different groups (One-way ANOVA test).
pSjS (n=30) RA (n=30) Control (n=28) p
Mean±St.
Dev.
Mean±St.
Dev.
Mean±St.
Dev.
MX1 serum 0.09±0.02 0.09±0.03 0.09±0.02 0.646
MX1 saliva 0.09±0.03 0.09±0.02 0.09±0.02 0.913
Table 2 - The correlation analysis of serum MX1 and clinical
parameters in the pSjS group (Pearson correlation analysis).
pSjS MX1 Serum
r p
Sialometry 0.056 0.768
ESSDAI score 0.113 0.552
Neutrophils 0.128 0.502
Hemoglobin 0.173 0.359
Sedimentation 0.221 0.241
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be a type 1 IFN bioactivity and was associated with disease
activity. In a study of 50 scleroderma patients, an increase in
MX1 expression was associated with severe disease findings,
such as decreased vital capacity and digital ulcers. MX1 has
been identified as the most practical biological marker to
evaluate IFN type I bioactivity in pSjS (8).
These findings suggested that high ESSDAI disease
activity scores in SjS may be related to a potential biomarker
of type 1 IFN, MX1. In a single study in the literature,
researchers evaluated 21 IFN-positive (IFN score of 10 and
more) and 14 IFN-negative (IFN score below 10) patients
with pSjS. These researchers compared the 35 patients who
had been diagnosed according to 2002 American-European
criteria and treated with high-dose prednisolone (more than
a 10 mg daily dose) without immunosuppressive drug and
biologic drug use with 27 healthy individuals without
autoimmune disease and with no corticosteroid use. These
researchers found a significant positive relationship between
the IFN scores and ESSDAI disease activity scores that were
used to measure the total type 1 IFN bioactivity and serum
MX1 levels. Maria et al. (3) found high MX1 levels in active
pSjS patients and found an association between high MX1
levels with higher ESSDAI scores, RF, SS-A or SS-B anti-
bodies, and immunoglobulin but with lower hemoglobin
and neutrophil values. At the end of this study, these
researchers suggested that MX1 might be a biomarker for
disease activation. Interestingly, in the same study, the MX1
levels were lower in the group using hydroxychloroquine
than in the other patient groups. This could explain our
nonsignificant results.
In the present study, we evaluated the effectiveness of the
MX1 protein in both the saliva and serum samples of pSjS
patients for the detection of disease activation. Contrary to
the study described above, we did not find any relationship
between serum and saliva MX1 levels and disease activity.
All of our patients with pSjS were using hydroxychloro-
quine. However, in the study by Maria NI et al. (3), serum
MX1 values were also found to decrease in patients treated
with hydroxychloroquine. These authors suggested that MX1
might be useful for predicting the therapeutic response to
hydroxychloroquine. In another study, hydroxychloroquine
was shown to affect systemic IFN formation (9). In our
patient group, the use of hydroxychloroquine and the low
ESSDAI disease activity scores in all patients may explain the
low MX1 levels that we detected. Malignancy has also been
widely discussed in the literature because the chronic use of
Table 3 - The MX1 serum evaluation in the pSjS group according to the clinical parameters.
pSjS MX1 Serum p
Mean±St. Dev.
ESSDAI score o7 (n=28) 0.09±0.02 (0.08) 10.560
47 (n=2) 0.09±0.01 (0.09)
Schirmer test o5 (n=24) 0.09±0.02 (0.08) 10.312
45 (n=6) 0.08±0.01 (0.08)
Raynaud phenomenon Positive (n=14) 0.08±0.01 20.029*
Negative (n=16) 0.09±0.03
Lymphadenopathy Positive (n=9) 0.08±0.02 (0.08) 10.377
Negative (n=21) 0.09±0.02 (0.08)
Parotid involvement Positive (n=2) 0.11±0.03 (0.11) 10.074
Negative (n=28) 0.08±0.02 (0.08)
Arthralgia/Arthritis Positive (n=23) 0.08±0.02 (0.08) 10.641
Negative (n=7) 0.09±0.02 (0.09)
Skin involvement Positive (n=8) 0.08±0.02 (0.08) 10.280
Negative (n=22) 0.09±0.02 (0.02)
Pulmonary involvement Positive (n=2) 0.08±0.01 (0.08) 10.677
Negative (n=28) 0.09±0.02 (0.08)
Cryoglobulinemia Positive (n=4) 0.09±0.01 (0.08) 10.760
Negative (n=26) 0.09±0.02 (0.08)
Complement allowance Positive (n=4) 0.08±0.01 (0.08) 10.502
Negative (n=26) 0.09±0.02 (0.08)
Neutropenia Positive (n=13) 0.08±0.02 20.162
Negative (n=17) 0.09±0.03
(1Mann-Whitney U test, 2Student’s t test, *po0.05)
Table 4 - The evaluation of serum MX1 compared to
autoantibody levels (Student’s t test).
MX1 Serum p
Mean±St. Dev.
Anti-RO (SS-A antibody) Positive (n=23) 0.08±0.02 0.353
Negative (n=37) 0.09±0.03
Anti-LA (SS-B antibody) Positive (n=18) 0.09±0.02 0.787
Negative (n=42) 0.09±0.03
RF Positive (n=27) 0.09±0.03 0.098
Negative (n=33) 0.08±0.02
ANA Positive (n=49) 0.08±0.02 0.072
Negative (n=11) 0.10±0.04
Table 5 - The correlation analysis of serum MX1 levels and
laboratory parameters (Pearson correlation analysis, *po0.05).
MX1 Serum
r p
Hemoglobin 0.273 0.035*
C3 0.013 0.944
C4 0.229 0.223
IgA 0.112 0.555
IgG 0.007 0.969
IgM 0.147 0.438
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hydroxychloroquine, especially for gastrointestinal manifes-
tations, hinders autophagy and systemic inflammation, thus
probably having some antineoplastic effects. However, these
theories are still debated (10,11).
Recent studies have shown that the activated type 1 IFN
pathway plays a crucial role in autoimmune diseases (4). In a
study that used an ELISA and real-time PCR to measure type
I IFN expression at the transcriptional and protein levels in
labial salivary gland biopsies, plasma, and peripheral blood
cells and performed immunohistochemistry in pSjS samples,
it was found that the IFN-a level was high in the patients’
labial salivary glands, as well as in their plasma and peri-
pheral blood cells (5). SLE, SjS, dermatomyositis, and psoria-
sis are the main diseases in which the IFN pathway has been
shown to important in genetic studies. In particular, the
study of SLE provide additional beneficial information to aid
in the understanding of the pathogenesis of pSjS (6,7). For
example, the transactivation of type I IFN and IFN-inducible
genes causes the polymorphism of interferon regulatory
factor (IRF5), which is also known to be related to SLE. In
addition, a relationship between the CGGGG insertion or
deletion polymorphism of the IRF5 promoter and pSjS was
identified. Increased mRNA levels of IRF5 in circulating
blood mononuclear cells and in the epithelial cells of the
salivary glands in patients who had four repeats of the
CGGGG IRF5 allele were positively correlated with the levels
of mRNA for IFN-inducible genes and MX1 (8,9).
The limitation of this study, which also negatively influ-
enced our results, was that the patient group was being
treated with hydroxychloroquine before, during and after
our measurements, since the ethics committee did not permit
us to discontinue the drug during the study. However,
a reliable marker should not be affected by treatment methods.
Moreover, the evaluation of the patients admitted to only
two university hospitals resulted in a randomization bias,
as is the case in most similar studies. However, MX1 was
detected at low levels despite both the low disease activity
score and hydroxychloroquine use (10). Since a minority
of patients had high ESSDAI scores, the analysis of the
relationship of ESSDAI scores with MX1 may have been
impaired. The clinical and laboratory parameters as well as
the ESSDAI levels were assessed in some of the pSjS patients.
However, it is unlikely that the increased ESSDAI scores
were an effect of reduced hydroxychloroquine use. Few
studies have been conducted on this topic. When compared
with those of other studies, our results may have been
affected by the use of hydroxychloroquine (11).
In conclusion, in the present study, we evaluated the rela-
tionship between serum and saliva MX1 levels and disease
activity scores (ESSDAI) in patients with pSjS. To date, there
has been no laboratory marker available for measuring
disease activation. In the SjS group, there was a statistically
significant positive correlation between the serum levels
of MX1 and hemoglobin levels (27.3%). The mean serum
level of MX1 in patients who were negative for Raynaud
phenomenon was significantly higher than that in patients
who were positive for Raynaud phenomenon. This difference
had a very borderline level of statistical significance, and
there was a very small difference in the MX1 levels. No
statistically significant association was found in the other
clinical and laboratory parameters. We believe that the low
MX1 levels in our series suggest that this marker can only be
used in a select group of patients, such as for monitoring the
effect of hydroxychloroquine in patients with high MX1
levels before treatment begins. MX1 levels play a consider-
able role in impacting the disease activity assessment of SS.
We believe that more comprehensive studies should be
carried out in patients with pSjS who do not use hydroxy-
chloroquine to prove these relationships for MX1 levels to be
used as a routine marker for the assessment of pSjS disease
activity. Further studies are necessary on both female and
male patients with pSjS who do not use hydroxychloroquine
to better understand the relationship between the diagnosis
of pSjS and MX1, which may reveal novel potential path-
ways for new therapeutic modalities.
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